Sánchez-Fauquier Alicia, Wilhelmi Isabel, Colomina Javier, Cubero Eusebio, Roman Enriqueta
Servicio de Virología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.
J Clin Microbiol. 2004 Apr;42(4):1609-13. doi: 10.1128/JCM.42.4.1609-1613.2004.
The incidence and distribution of human rotavirus G types among children under 5 years old with acute gastroenteritis were determined over a 4-year period (1998 to 2002) by using monoclonal antibodies and reverse transcription-PCR methods. Rotavirus was detected in 1,155 (31%) of 3,760 specimens tested. Rotavirus was studied in every month of the 48-month survey period. Rotavirus activity occurred mainly (51%) in the typically cooler months in Spain (November to February). The age distribution of rotavirus-positive cases showed that 90% of patients (1,038 of 1,155) were under 2 years old. Rotavirus types were determined for 576 of 1,155 patients (50%). G1 was the main genotype detected (53%), and the second most common was G4 (24%). The G2, G9, and G3 rotavirus types were detected in 14, 6, and 2% of the cases, respectively. Dual infections were detected in only 0.6%. The seasonal distribution of genotypes showed a significant genotypic shift: whereas G4 strains predominated (57%) during the 1998 to 2000 seasons, the G1 gradually increased to account for 75% in the 2000 to 2002 seasons. In addition, the present study reports the first detection of the G9 genotype in human fecal samples in Spain. Therefore, additional types may be required for vaccine development strategies that currently target only types G1 to G4.
在1998年至2002年的4年期间,采用单克隆抗体和逆转录-聚合酶链反应方法,确定了5岁以下急性胃肠炎儿童中人类轮状病毒G型的发病率和分布情况。在3760份检测标本中,有1155份(31%)检测到轮状病毒。在为期48个月的调查期内,每个月都对轮状病毒进行了研究。轮状病毒活动主要(51%)发生在西班牙较为凉爽的月份(11月至2月)。轮状病毒阳性病例的年龄分布显示,90%的患者(1155例中的1038例)年龄在2岁以下。对1155例患者中的576例(50%)进行了轮状病毒分型。检测到的主要基因型是G1(53%),第二常见的是G4(24%)。G2、G9和G3轮状病毒型分别在14%、6%和2%的病例中被检测到。仅0.6%的病例检测到双重感染。基因型的季节分布显示出显著的基因型转变:在1998年至2000年季节,G4毒株占主导(57%),而在2000年至2002年季节,G1逐渐增加至占75%。此外,本研究报告了在西班牙人类粪便样本中首次检测到G9基因型。因此,目前仅针对G1至G4型的疫苗开发策略可能需要增加其他类型。